IL5 and eosinophilic granulomatosis with polyangiitis: Ongoing clinical trials with anti-IL5 agents [benralizumab (Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab (MANDARA) Trial NCT04157348) and depemokimab (Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory EGPA (OCEAN) Trial; NCT05263934)] will assess their effectiveness compared with mepolizumab in EGPA.